Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TUB-040 |
Synonyms | |
Therapy Description |
TUB-040 is an antibody-drug conjugate (ADC) comprising an antibody targeting SLC34A2 (NAPI2B) linked to a topoisomerase 1 inhibitor, which induces DNA damage and apoptosis, potentially resulting in tumor growth inhibition (Cancer Res (2024) 84 (6_Supplement): 2622). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TUB-040 | TUB040|TUB 040 | TUB-040 is an antibody-drug conjugate (ADC) comprising an antibody targeting SLC34A2 (NAPI2B) linked to a topoisomerase 1 inhibitor, which induces DNA damage and apoptosis, potentially resulting in tumor growth inhibition (Cancer Res (2024) 84 (6_Supplement): 2622). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06303505 | Phase Ib/II | TUB-040 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC (NAPISTAR1-01) | Recruiting | USA | ESP | DEU | BEL | 1 |